BlackRock’s Kindred Biosciences, Inc. KIN Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2021
Q3 | – | Sell |
-817,300
| Closed | -$7.5M | – | 5755 |
|
|
2021
Q2 | $7.5M | Sell |
817,300
-1,897,770
| -70% | -$11M | ﹤0.01% | 3752 |
|
|
2021
Q1 | $13.5M | Buy |
2,715,070
+42,957
| +2% | +$207K | ﹤0.01% | 3409 |
|
|
2020
Q4 | $11.5M | Buy |
2,672,113
+108,527
| +4% | +$441K | ﹤0.01% | 3288 |
|
|
2020
Q3 | $11M | Buy |
2,563,586
+81,934
| +3% | +$342K | ﹤0.01% | 3171 |
|
|
2020
Q2 | $11.1M | Buy |
2,481,652
+19,390
| +0.8% | +$86.7K | ﹤0.01% | 3122 |
|
|
2020
Q1 | $9.85M | Buy |
2,462,262
+6,389
| +0.3% | +$54.3K | ﹤0.01% | 3000 |
|
|
2019
Q4 | $20.8M | Buy |
2,455,873
+4,690
| +0.2% | +$36.6K | ﹤0.01% | 2855 |
|
|
2019
Q3 | $16.8M | Buy |
2,451,183
+58,098
| +2% | +$426K | ﹤0.01% | 2920 |
|
|
2019
Q2 | $19.9M | Buy |
2,393,085
+425,237
| +22% | +$3.67M | ﹤0.01% | 2849 |
|
|
2019
Q1 | $18M | Buy |
1,967,848
+124,329
| +7% | +$1.26M | ﹤0.01% | 2793 |
|
|
2018
Q4 | $20.2M | Buy |
1,843,519
+14,126
| +0.8% | +$178K | ﹤0.01% | 2717 |
|
|
2018
Q3 | $25.5M | Buy |
1,829,393
+504,246
| +38% | +$6.82M | ﹤0.01% | 2732 |
|
|
2018
Q2 | $14.1M | Buy |
1,325,147
+221,578
| +20% | +$2.16M | ﹤0.01% | 3062 |
|
|
2018
Q1 | $9.55M | Sell |
1,103,569
-12,140
| -1% | -$107K | ﹤0.01% | 3149 |
|
|
2017
Q4 | $10.5M | Buy |
1,115,709
+42,777
| +4% | +$334K | ﹤0.01% | 3117 |
|
|
2017
Q3 | $8.42M | Buy |
1,072,932
+128,363
| +14% | +$963K | ﹤0.01% | 3263 |
|
|
2017
Q2 | $8.12M | Buy |
944,569
+845,813
| +856% | +$6.07M | ﹤0.01% | 3281 |
|
|
2017
Q1 | $695K | Buy |
+98,756
| New | +$619K | ﹤0.01% | 3888 |
|
|
2014
Q3 | – | Sell |
-243
| Closed | -$5K | – | 3196 |
|
|
2014
Q2 | $5K | Hold |
243
| – | – | ﹤0.01% | 3123 |
|
|
2014
Q1 | $5K | Buy |
+243
| New | +$4.63K | ﹤0.01% | 3056 |
|
Other funds holding KIN
BlackRock's KIN Position: Q3 2021 in Review
BlackRock sold out of Kindred Biosciences, Inc. (KIN) in Q3 2021, closing a stake of 817,300 shares — an estimated $7.5M sold.
BlackRock first reported a position in KIN in Q1 2014 and held it in 20 quarters. The position peaked at $25.5M in Q3 2018. 1 fund tracked by Wall St. Rank holds KIN as of Q3 2021.
- BlackRock reported no remaining Kindred Biosciences, Inc. position as of Q3 2021 after selling out during the quarter.
- BlackRock sold 817,300 Kindred Biosciences, Inc. shares in Q3 2021, an estimated $7.5M.
- BlackRock first reported a position in Kindred Biosciences, Inc. in Q1 2014 and held it in 20 quarters.
- BlackRock's Kindred Biosciences, Inc. position peaked at $25.5M in Q3 2018.
- 1 fund tracked by Wall St. Rank held Kindred Biosciences, Inc. as of Q3 2021.
Based on BlackRock's 13F filing for Q3 2021, filed 9 Nov 2021.